CLEVELAND, April 11, 2024 /PRNewswire/ -- More hope for successfully combating some of the deadliest cancers. Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials.
Lamassu Awarded NIH Grant For Breakthrough Cancer Treatment